Evolution of frameworks for expediting access to new drugs in Japan

被引：28

作者：

Fujiwara, Yasuhiro ^{[1
,2
]}

机构：

[1] Natl Canc Ctr, Natl Canc Ctr, Strateg Planning Bur, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan

[2] Natl Canc Ctr, Dept Breast & Med Oncol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan

来源：

NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 05期

关键词：

D O I：

10.1038/nrd.2016.68

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Japanese clinical research and regulatory frameworks have evolved considerably in the past two decades to reduce the delay in the introduction of new drugs in Japan compared with other major markets. However, recently introduced changes related to access to unapproved drugs might have the opposite effect and might not benefit all patients.

引用

页码：293 / 294

页数：2

共 3 条

[1] Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC) [J].

Fujiwara, Y ;

Kobayashi, K .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 42 (02) :145-155

[2] Japanese universal health care faces a crisis in cancer treatment [J].

Fujiwara, Yasuhiro ;

Yonemori, Kan ;

Shibata, Taro ;

Okita, Natsuko ;

Ushirozawa, Nobuko .

LANCET ONCOLOGY, 2015, 16 (03) :251-252

[3]

Kagayama K., 2015, RES PAPER SERIES, V68

← 1 →